Literature DB >> 16951565

Agonist of proteinase-activated receptor 2 increases painful behavior produced by alpha, beta-methylene adenosine 5'-triphosphate.

Wan-Jun Zhu1, Yi Dai, Tetsuo Fukuoka, Hiroki Yamanaka, Kimiko Kobayashi, Koichi Obata, Shenglan Wang, Koichi Noguchi.   

Abstract

Proteinase-activated receptor (PAR) 2 is expressed in a subset of primary afferent neurons and is involved in inflammatory nociception. The P2X3 ion channel is localized on nociceptors of sensory neurons. Using immunohistochemistry, we showed that many P2X3s are co-expressed with the PAR2 in rat dorsal root ganglia neurons. Nocifensive behavior induced by alphabeta-methylene adenosine 5'-triphosphate (ATP) injection to the hind paw was significantly augmented after the application of PAR2 agonists. Fos expression induced by the alphabeta-methylene ATP injection in dorsal horn neurons was also increased after the pre-application of PAR2 agonists. These findings indicate that PAR2 agonists may potentiate the sensitivity of P2X3 ion channel to noxious stimuli, and the interaction between PAR2 and P2X3 may be an important mechanism underlying inflammatory pain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951565     DOI: 10.1097/01.wnr.0000230518.31833.5d

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  3 in total

Review 1.  P2X3 receptor involvement in pain states.

Authors:  Kerstin Wirkner; Beata Sperlagh; Peter Illes
Journal:  Mol Neurobiol       Date:  2007-07-17       Impact factor: 5.590

2.  Expression of leukotriene receptors in the rat dorsal root ganglion and the effects on pain behaviors.

Authors:  Masamichi Okubo; Hiroki Yamanaka; Kimiko Kobayashi; Tetsuo Fukuoka; Yi Dai; Koichi Noguchi
Journal:  Mol Pain       Date:  2010-09-17       Impact factor: 3.395

3.  Brachystemma calycinum D. Don Effectively Reduces the Locomotor Disability in Dogs with Naturally Occurring Osteoarthritis: A Randomized Placebo-Controlled Trial.

Authors:  Maxim Moreau; Bertrand Lussier; Jean-Pierre Pelletier; Johanne Martel-Pelletier; Christian Bédard; Dominique Gauvin; Eric Troncy
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-15       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.